Navigation Links
Genmab Reaches Milestones in Ofatumumab Collaboration
Date:1/21/2008

ensive pipeline of products for potential treatment of a variety of diseases including cancer and autoimmune disorders.

As Genmab advances towards a commercial future, we remain committed to our primary goal of improving the lives of patients who are in urgent need of new treatment options. For more information on Genmab's products and technology, visit http://www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.

Contact:

H
'/>"/>

SOURCE Genmab A/S
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Genmab Announces HuMax-CD32b Pre-Clinical Program
2. Roche Files IND for Second Genmab Antibody
3. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
4. Genmab Announces Details of Planned Ofatumumab Phase II Study in Multiple Sclerosis
5. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
6. Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
7. Genmab Announces Results for the First Nine Months of 2007
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
10. Genmab A/S - Company Announcement
11. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... occurs when the transplant recipient,s immune system identifies the ... was previously thought that T cells, the immune cells ... known as chemokines in order to migrate to the ... of Clinical Investigation , Fadi Lakkis and colleagues at ... chemokine stimulation of T cells is not required for ...
(Date:5/17/2013)... 2013 The new Public-Private Partnership (PPP) ... the association’s recent annual meeting drew praise from community ... Kroes, who called the action “a huge step forward ... to European innovation.” , The Board of Stakeholders voted ... Photonics PPP at its 29 April meeting in Brussels, ...
(Date:5/17/2013)... 17, 2013  Cellular Biomedicine Group (OTCQB: CBMG) ... of the total projected enrollment required for its ... preliminary efficacy of the medical technology haMPC (Human ... (KOA). To date the trial has had no ... Phase I open label clinical research trial for ...
(Date:5/17/2013)... May 17, 2013  Insero Health, Inc., a company ... epilepsy and related neurological disorders, is today reporting top-line ... compound INS001 in patients with drug-resistant epilepsy.  The data ... Trials (AED) Xll meeting by Dr. Steven ... of Insero,s Scientific Advisory Board.  In this study, INS001 ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... CHESTNUT HILL, MA (12/11/2009) Boston College researchers have observed ... first time and successfully harvested the elusive charges using ultra-thin ... efficiency, the authors report in the current online edition of ... in solar cells, it generates free electrons in a range ...
... , , , CAMBRIDGE, Mass., Dec. ... and biotechnology company specializing in cancer, staph aureus, and ... Pre-clinical Services announced today that Rosalie Dunn, Ph.D., has ... has over 28 years of experience working with small ...
... 10 Microban International, Ltd., the global leader in ... and Information Company of America, a division of Sharp ... into Sharp,s new printing calculators. Infused into the calculator ... the growth of damaging bacteria on the keys. ...
Cached Biology Technology:Elusive 'hot' electrons captured in ultra-thin solar cells 2Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2
(Date:5/17/2013)... The State University of New Jersey, and City University ... called Visikol TM that effectively clears organisms to ... place of chloral hydrate, which is one of the ... tightly regulated by the Drug Enforcement Administration (DEA) due ... or clearing agents, are vital for viewing organisms under ...
(Date:5/17/2013)... new Dartmouth College study finds human-caused climate change ... tropical lizards, contradicting a host of recent studies ... warming planet. , The findings, which appear in ... new hope for survival of a creature thought ... predictions that tropical cold-blooded animals, especially forest lizards, ...
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) ... The Society for Developmental Biology (SDB) 72nd Annual ... These awards are meant to promote the entry ... into the mainstream of the basic science community ... at the SDB 2013 Annual Meeting. , Awards ...
Breaking Biology News(10 mins):New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3Climate change may have little impact on tropical lizards 2
... Oliver Daumke, structural biologists at the Max Delbrck Center ... Freie Universitt (FU) Berlin, have determined the molecular structure ... the cell. Since pathogens such as HIV can also ... underlying molecular mechanisms can potentially open up new approaches ...
... protect the human brain against neurodegenerative disorders such as ... research. A technology developed at Tel Aviv University does ... and in hospitals to begin clinical trials with patients ... Lou Gehrig,s disease. Developed by Prof. Daniel ...
... Online gamers have solved the structure of a ... players were adept at a computer game, Foldit, that ... structure of protein molecules. After scientists repeatedly failed ... from an AIDS-like virus, they called in the Foldit ...
Cached Biology News:Spiral constriction -- how dynamin mediates cellular nutrient uptake 2Using bone marrow to protect the brain 2Online gamers succeed where scientists fail, opening door to new AIDS drug design 2Online gamers succeed where scientists fail, opening door to new AIDS drug design 3
... Yeast ProtoArray high-density functional protein microarray is ... elucidation of proteinprotein interactions on a proteome ... cerevisiae open reading frames (ORFs) expressed as ... on a 1 inch x 3 inch ...
... Yeast nitrogen base (YNB) is a base medium ... media. YNB contains ammonium sulfate but does not ... pouches are available. Each pouch contains reagents ... Pichia media or 1000 ml of 10X YNB ...
... interferons are cytopathic effect inhibition assays, also ... The neutralization assay measures the antibody's ability ... cytokine. Sample types include; tissue culture supernatents; ... assays, one unit is defined as the ...
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
Biology Products: